NanoViricides
NNVC
30 hedge funds and large institutions have $1.51M invested in NanoViricides in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
192% more call options, than puts
Call options by funds: $312K | Put options by funds: $107K
0.23% more ownership
Funds ownership: 11.52% → 11.75% (+0.23%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
3% less funds holding
Funds holding: 31 → 30 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
34% less capital invested
Capital invested by funds: $2.3M → $1.51M (-$787K)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$81.6K |
| 2 |
Millennium Management
New York
|
+$39K |
| 3 |
VF
Virtu Financial
New York
|
+$18.1K |
| 4 |
Renaissance Technologies
New York
|
+$9.21K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.58K |
Top Sellers
NNVC Hedge Fund Activity: Q4 2022 in Review
30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in NanoViricides (NNVC) for Q4 2022, worth a combined $1.51M — down 34% from $2.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NNVC and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, adding an estimated $81.6K. The largest seller was Morgan Stanley, cutting an estimated $36.9K.
- 30 institutional investors held NanoViricides (NNVC) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $1.51M of NanoViricides stock for Q4 2022, down 34% quarter-over-quarter.
- 5 funds opened new NanoViricides positions in Q4 2022 and 6 closed out, a net change of -1 holder.
- The largest NanoViricides buyer in Q4 2022 was Citadel Advisors, an estimated $81.6K added.
- The largest NanoViricides seller in Q4 2022 was Morgan Stanley, an estimated $36.9K sold.
Based on aggregated 13F filings for Q4 2022.